Literature DB >> 23730529

Hippocampal oscillatory activity in Alzheimer's disease: toward the identification of early biomarkers?

Romain Goutagny1, Slavica Krantic.   

Abstract

Alzheimer's disease (AD) develops for a yet unknown period of time and can progress undiagnosed for years before its first clinical manifestation consisting of characteristic cognitive impairments. Current AD treatments offer only a small symptomatic benefit, likely because AD is diagnosed when the pathology is already well advanced, whereas treatments may be most efficient in the early phases of pathology. An accurate, early marker of AD is therefore needed to help diagnose AD earlier. It is now well documented that AD patients and animal models of AD exhibit reorganization of hippocampal and cortical networks. This reorganization is initiated by an early imbalance between excitation and inhibition, leading to altered network activity. The mechanisms underlying these changes are unknown but recent evidence suggests that either soluble amyloid-beta (Aß) or fibrillar forms of Aß are central to various network alterations observed in AD. However, recent evidence also suggests that Aβ over-production in animal models is not systematically linked to network over-excitation. We hypothesize here that early changes in the excitation-inhibition balance within the hippocampus occurs much earlier than currently believed and initially produces only slight changes in overall hippocampal activity. In this review, we introduce the concept according to which the subtle changes in theta and gamma rhythms might occur during the very first stages of AD and thus could be used as a possible predictor for the disease.

Entities:  

Keywords:  Aβ; Oscillatory activity; gamma oscillations; hippocampus; theta rhythm

Year:  2013        PMID: 23730529      PMCID: PMC3660123     

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  50 in total

1.  Hippocampal electrical activity and voluntary movement in the rat.

Authors:  C H Vanderwolf
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1969-04

2.  Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.

Authors:  Laure Verret; Edward O Mann; Giao B Hang; Albert M I Barth; Inma Cobos; Kaitlyn Ho; Nino Devidze; Eliezer Masliah; Anatol C Kreitzer; Istvan Mody; Lennart Mucke; Jorge J Palop
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

3.  Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus.

Authors:  David Baglietto-Vargas; Ines Moreno-Gonzalez; Raquel Sanchez-Varo; Sebastian Jimenez; Laura Trujillo-Estrada; Elisabeth Sanchez-Mejias; Manuel Torres; Manuel Romero-Acebal; Diego Ruano; Marisa Vizuete; Javier Vitorica; Antonia Gutierrez
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 4.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 5.  Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations.

Authors:  Thomas Klausberger; Peter Somogyi
Journal:  Science       Date:  2008-07-04       Impact factor: 47.728

6.  Loss of hippocampal theta rhythm results in spatial memory deficit in the rat.

Authors:  J Winson
Journal:  Science       Date:  1978-07-14       Impact factor: 47.728

7.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

8.  Medial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function.

Authors:  Luis V Colom; Maria T Castañeda; Cristina Bañuelos; Gustavo Puras; Antonio García-Hernández; Sofia Hernandez; Suzanne Mounsey; Joy Benavidez; Claudia Lehker
Journal:  Neurobiol Aging       Date:  2008-06-10       Impact factor: 4.673

9.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Authors:  Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  17 in total

Review 1.  From Molecular Circuit Dysfunction to Disease: Case Studies in Epilepsy, Traumatic Brain Injury, and Alzheimer's Disease.

Authors:  Chris G Dulla; Douglas A Coulter; Jokubas Ziburkus
Journal:  Neuroscientist       Date:  2015-05-06       Impact factor: 7.519

2.  Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex.

Authors:  Javier Pacheco-Quinto; Christopher B Eckman; Elizabeth A Eckman
Journal:  Neurobiol Aging       Date:  2016-08-20       Impact factor: 4.673

Review 3.  Neuronal Network Oscillations in Neurodegenerative Diseases.

Authors:  Volker Nimmrich; Andreas Draguhn; Nikolai Axmacher
Journal:  Neuromolecular Med       Date:  2015-04-29       Impact factor: 3.843

4.  Intrinsic Cornu Ammonis Area 1 Theta-Nested Gamma Oscillations Induced by Optogenetic Theta Frequency Stimulation.

Authors:  James L Butler; Philipe R F Mendonça; Hugh P C Robinson; Ole Paulsen
Journal:  J Neurosci       Date:  2016-04-13       Impact factor: 6.167

5.  Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer's disease.

Authors:  Julie C Lauterborn; Pietro Scaduto; Conor D Cox; Anton Schulmann; Gary Lynch; Christine M Gall; C Dirk Keene; Agenor Limon
Journal:  Nat Commun       Date:  2021-05-10       Impact factor: 14.919

Review 6.  GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.

Authors:  Mauricio O Nava-Mesa; Lydia Jiménez-Díaz; Javier Yajeya; Juan D Navarro-Lopez
Journal:  Front Cell Neurosci       Date:  2014-06-25       Impact factor: 5.505

7.  Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.

Authors:  Magdalena Elisabeth Siwek; Ralf Müller; Christina Henseler; Astrid Trog; Andreas Lundt; Carola Wormuth; Karl Broich; Dan Ehninger; Marco Weiergräber; Anna Papazoglou
Journal:  Neural Plast       Date:  2015-04-02       Impact factor: 3.599

8.  p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's disease.

Authors:  Arne A Ittner; Amadeus Gladbach; Josefine Bertz; Lisa S Suh; Lars M Ittner
Journal:  Acta Neuropathol Commun       Date:  2014-10-21       Impact factor: 7.801

9.  Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease.

Authors:  Anna Papazoglou; Julien Soos; Andreas Lundt; Carola Wormuth; Varun Raj Ginde; Ralf Müller; Christina Henseler; Karl Broich; Kan Xie; Dan Ehninger; Britta Haenisch; Marco Weiergräber
Journal:  Neural Plast       Date:  2016-10-20       Impact factor: 3.599

Review 10.  Precocious Alterations of Brain Oscillatory Activity in Alzheimer's Disease: A Window of Opportunity for Early Diagnosis and Treatment.

Authors:  Valentine Hamm; Céline Héraud; Jean-Christophe Cassel; Chantal Mathis; Romain Goutagny
Journal:  Front Cell Neurosci       Date:  2015-12-21       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.